drugset / Trial / NCT02373098

Fingolimod Effect on Cytokine and Chemokine Levels

NCT02373098

Phase 4 Completed 126 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses. Cytokines are a broad and loose category of small proteins that are important in cell signaling. The second purpose of the study was to test the cytokine/chemokine changes measured in the 3rd and 6th months on the efficacy parameters.

Timeline

Start
2015-03-31
Primary completion
2017-01-18
Completion
2017-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg